In this week's rheumatology news roundup, we feature a Q&A with Dr. Aryeh M. Abeles who talks with Rheumatology Network about his concerns with the black box warning label for the gout treatment febuxostat. We also include a story on addressing prescription abdandonment in rheumatoloyg. These and other stories in today's news roundup.
In this week's rheumatology news roundup, we feature a Q&A with Dr. Aryeh M. Abeles who talks with Rheumatology Network about his concerns with the black box warning label for the gout treatment febuxostat. We also include a story on addressing prescription abdandonment in rheumatoloyg. These and other stories in today's news roundup.
Black Box Blues for Gout Treatment Febuxostat. Aryeh M. Abeles, M.D., talks with Rheumatology Network about the FDA's black box label for febuxostat, a gout treatment which, according to the results of one clinical trial, was shown to be associated with an increased risk of mortality. In this Q&A, Dr. Abeles, says the decision was based on flawed data.
Introducing The Lancet Rheumatology.This week, the British medical journal The Lancet, launched a new journal that focuses strictly on rheumatology. Aptly called "The Lancet Rheumatology," the journal's mission is to "provide an independent voice to the rheumatology community and to the millions of patients living with these conditions."